 |
|
|
| |
Viremia and drug resistance over 2 years after routine switching to dolutegravir-based first-line ART
|
| |
| |
CROI 2024 March 3-6 Denver
Veronika Whitesell Skrivankova1, Jacqueline Huwa2, Guy Muula3, Geldert D Chiwaya2, Esau Banda3, Shameem Buleya2, Belinda Chihota3, Joseph Chintedza2, Carolyn Bolton3, Thokozani Kalua4, Roger Kouyos5, Gilles Wandeler6, Matthias Egger7, Richard J Lessells8
1Institute of Social and Preventive Medicine, Bern, Switzerland 2Lighthouse Trust, Lilongwe, Malawi 3Centre for Infectious Disease Research in Zambia, Lusaka, Zambia 4Center for International Health, Education and Biosecurity (Ciheb) at UMB, Lilongwe, Malawi 5University Hospital Zurich, Zurich, Switzerland 6University Hospital of Bern, Bern, Switzerland 7University of Bern, Bern, Switzerland 8KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa
Those with viremia likely had adherence problems which means they also probably had NRTI resistance as well.
|
| |
|
|
|
|
|
